Sabre Corpo vs Orsted A/S
A head-to-head of Sabre Corpo (SABR) and Orsted A/S (DOGEF) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | SABR | DOGEF |
|---|---|---|
| Market Cap | $727.12M | $537.44B |
| P/E (TTM) | 1.36 | 126.35 |
| Forward P/E | 37.74 | 0.66 |
| P/S | 0.26 | 7.34 |
| P/B | 145.10 | 2.00 |
| EV/EBITDA | 13.77 | 15.58 |
| Dividend Yield | — | — |
| Profit Margin | 18.44% | 2.97% |
| Gross Margin | 56.44% | -2.70% |
| Operating Margin | 12.66% | -2.70% |
| Revenue Growth (YoY) | -6.74% | +12.75% |
| FCF Yield | -29.35% | -5.87% |
| Debt / Equity | — | 83.48 |
| Current Ratio | 1.07 | 1.94 |
Which is better: Sabre Corpo or Orsted A/S?
- ✓Larger by market cap: Orsted A/S
- ✓Cheaper valuation (lower P/E): Sabre Corpo
- ✓More profitable (net margin): Sabre Corpo
- ✓Faster revenue growth: Orsted A/S
- ✓Higher free-cash-flow yield: Orsted A/S
Across 11 available metrics, Sabre Corpo leads 6–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Sabre Corpo with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.